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Atherothrombosis, characterized by atherosclerotic lesion disruption with superimposed thrombus formation, is 
the major cause of acute coronary syndromes and cardiovas-
cular death. Predominantly, platelet-rich (white) thrombi are 
formed at the ruptured area, because platelet recruitment pref-
erentially occurs at regions of high shear rate and disturbed 
flow, whereas maximal fibrin generation occurs in regions of 
low flow.1 Activated platelets support the tissue factor (TF) 
pathway of blood coagulation by binding various (anti)coagu-
lation factors.2 There is emerging evidence that platelets also 
support the intrinsic coagulation pathway mediated by factors 
XII (FXII) and XI (FXI), for example, by releasing polyphos-
phates, although the exact mechanism is still unclear.3–5 Better 
understanding of these multifaceted roles of platelets in coag-
ulation stimulation can lead to new approaches to selectively 
inhibit the pathways most relevant in atherothrombosis.
See accompanying editorial on page 1607
Collagen type I is not only the most potent platelet activating 
component in atherosclerotic plaques by binding and activating 
the glycoprotein VI receptor,6–8 but has also has been shown to 
bind to and activate FXII.9 Several mouse studies using nonath-
erosclerotic vessels point to a consolidating role of the FXII path-
way in arterial thrombus formation and thrombus stabilization, 
as concluded from experiments with genetic ablation or phar-
macological inhibition of FXII.4,10–13 Interestingly, deficiency in 
FXII in man or mouse is not accompanied by abnormal bleed-
ing.3,14 On the contrary, individuals with partly reduced FXII lev-
els have an increased risk of cardiovascular disease (reviewed in 
Renné et al15 and Woodruff et al16), which indicates that the clini-
cal consequences of (partial) FXII deficiency are more complex 
than the reported antithrombotic effects of FXII ablation in mice.
To date, no experimental data exist on a role of the intrin-
sic coagulation pathway in pathological thrombus formation 
after atherosclerotic plaque rupture. A recent report studying 
plaque-induced thrombin generation in vitro suggested that 
the intrinsic FXII pathway may not play a key role in this pro-
cess, such in contrast to a predominant role for plaque-derived 
TF triggering the extrinsic pathway.8 In the present article, we 
therefore compared the roles of both the extrinsic and intrinsic 
coagulation pathways in thrombus formation on atheroscle-
rotic plaques in vivo and ex vivo.
© 2014 American Heart Association, Inc.
Arterioscler Thromb Vasc Biol is available at http://atvb.ahajournals.org DOI: 10.1161/ATVBAHA.114.303315
Objective—Atherothrombosis is the main cause of myocardial infarction and ischemic stroke. Although the extrinsic (tissue 
factor–factor VIIa [FVIIa]) pathway is considered as a major trigger of coagulation in atherothrombosis, the role of the 
intrinsic coagulation pathway via coagulation FXII herein is unknown. Here, we studied the roles of the extrinsic and 
intrinsic coagulation pathways in thrombus formation on atherosclerotic plaques both in vivo and ex vivo.
Approach and Results—Plaque rupture after ultrasound treatment evoked immediate formation of subocclusive thrombi 
in the carotid arteries of Apoe−/− mice, which became unstable in the presence of structurally different FXIIa inhibitors. 
In contrast, inhibition of FVIIa reduced thrombus size at a more initial stage without affecting embolization. Genetic 
deficiency in FXII (human and mouse) or FXI (mouse) reduced ex vivo whole-blood thrombus and fibrin formation on 
immobilized plaque homogenates. Localization studies by confocal microscopy indicated that FXIIa bound to thrombi 
and fibrin particularly in luminal-exposed thrombus areas.
Conclusions—The FVIIa- and FXIIa-triggered coagulation pathways have distinct but complementary roles in atherothrombus 
formation. The tissue factor–FVIIa pathway contributes to initial thrombus buildup, whereas FXIIa bound to thrombi 
ensures thrombus stability.  (Arterioscler Thromb Vasc Biol. 2014;34:1674-1680.)
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Materials and Methods
Materials and methods are available in the online-only Supplement.
Results
Distinct Roles of Murine FXII and FVII 
Pathways in Arterial Thrombus Formation 
on Ruptured Atherosclerotic Plaques
In mouse models, the role of FXII in thrombus formation 
has only been investigated on damage of healthy arteries. 
Here, we studied the contribution of FXII to the thrombotic 
process after acute rupture of an atherosclerotic plaque, using 
a recently established model of acute plaque rupture in the 
carotid bifurcation of Apoe−/− mice.17 In control Apoe−/− mice, 
ultrasound treatment of the plaque shoulder provoked rapid 
thrombus formation at the site of rupture (Figure 1A; Movie 
I in the online-only Data Supplement). The formed thrombi 
remained subocclusive and reduced in size because of plate-
let contraction and limited embolization during the first 10 
minutes after rupture, but then became stable for at least sev-
eral hours, as observed before.17 In mice injected with one of 
the FXIIa inhibitors, corn trypsin inhibitor (CTI; 4 mg/kg) 
or recombinant infestin-4 human albumin fusion protein 
(30 mg/kg), thrombus formation tended to be reduced, an 
effect that became significant 1 to 2 minutes after plaque rup-
ture (Figure 1A–1C). In addition, either inhibitor caused a sig-
nificant increase in shedding of discernable emboli from the 
initial thrombus (Figure 1D; Movie II in the online-only Data 
Supplement).
Interestingly, injection of active-site inactivated FVIIa 
(FVIIai; 1 mg/kg), known to block murine TF–FVIIa interac-
tions,18 reduced thrombus formation at a more initial stage, 
Nonstandard Abbreviations and Acronyms
CTI corn trypsin inhibitor





































































































































Figure 1. Distinct roles for factor XIIa 
(FXIIa) and FVIIa in arterial thrombus for-
mation after acute plaque rupture in vivo. 
Apoe−/− mice were injected with saline 
(control), corn trypsin inhibitor (CTI; 4  
mg/kg), recombinant infestin-4 human 
albumin fusion protein (rHA-infestin-4; 
30 mg/kg), active-site inactivated FVIIa 
(FVIIai; 1 mg/kg), or CTI (4 mg/kg) and 
FVIIai (1 mg/kg). Carotid plaques were 
ruptured by ultrasound after which 
thrombus formation was quantified from 
preinjected CFSE-labeled platelets. 
A, Bright-field images of carotid plaque 
(p) and threshold masked fluorescence 
images of thrombi before and after ultra-
sound treatment. Dotted lines indicate 
contours of carotid artery and plaque 
(bars, 200 μm). B, Time courses of inte-
grated carboxyfluorescein diacetate suc-
cinimidyl ester (CFSE) fluorescence (FL) 
intensity above background of thrombi 
formed (arbitrary units [AU]). Fluctua-
tions in fluorescence intensity indicate 
embolus shedding. C, Quantification 
of thrombus size at various time points 
after ultrasound treatment (integrated 
fluorescence intensities from threshold 
masked images). D, Numbers of fluo-
rescent emboli shed during 3 minutes 
after plaque rupture. Data are means±SE 
(n=7–11); *P<0.05 and #P=0.051 com-
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whereas embolization was not affected (Figure 1; Movie III in 
the online-only Data Supplement). In mice treated with FVIIai 
and CTI, thrombus formation at later, but not at early, time 
points was even further reduced (P values of 0.210, 0.074, 
0.015, and 0.031 at t=0.5, 1, 2, and 10 minutes, respectively). 
Taken together, this pointed to distinct but complementary 
roles of the FVIIa- and FXIIa-triggered coagulation path-
ways in the thrombotic process after plaque rupture. Herein, 
TF–FVIIa interaction seems to be needed for initial thrombus 
formation, whereas FXII ensures thrombus stability.
Role of Murine FXII in Flow-Dependent Thrombus 
Formation on Atherosclerotic Plaque Material
To study the role of murine FXII in plaque-induced thrombus 
formation in more detail, flow experiments were performed 
where blood from wild-type or factor-deficient mice was per-
fused at moderately high shear rate under coagulant condi-
tions (mmol/L Ca2+/Mg2+) over a surface coated with murine 
plaque material. With blood from wild-type mice, platelets 
rapidly adhered to the plaque and formed large thrombi. These 
thrombi contracted after several minutes, stained positively 
for exposed phosphatidylserine, and had fibrin fibers originat-
ing from them (Figure 2A). When using blood from F12−/− 
mice, initial platelet adhesion to the plaque material was 
unchanged, but ensuing thrombus formation and phosphati-
dylserine exposure (quantified as surface area coverage) were 
markedly diminished and no formed fibrin could visually be 
observed (Figure 2). Importantly, the defective thrombus for-
mation was almost fully restored after supplementation with 
purified human FXII.
The main downstream effector protein of FXII is FXI 
which, however, can also be activated independently of FXII 
via a feedback loop of thrombin.19,20 To study the role of FXI 
in plaque-induced thrombus formation, flow experiments 
were performed with blood from F11−/− and F11−/−/F12−/− 
mice. In either case, the thrombus-forming process was simi-
larly impaired as with F12−/− blood (Figure 2A, 2C, and 2D). 
Together, these data demonstrate a key role of murine FXII in 
thrombus and fibrin formation during whole-blood perfusion 
over a murine plaque surface mediated through the classical 
FXII–FXI reaction cascade.
Role of Human FXII in Flow-Dependent Thrombus 
Formation on Atherosclerotic Plaque Material
Having established the role of murine FXII in plaque-induced 
thrombus formation, we investigated the function of FXII 
also in the human system. Blood from control subjects and 
an FXII-deficient subject (FXII level <1%) was perfused 
over immobilized human plaque material under coagulation-
promoting conditions. With the FXII-deficient blood, ini-
tial platelet adhesion to the plaque surface was comparable 
with that of control blood samples. However, after 10 min-
utes of perfusion, the surface area covered by thrombi, the 
amount of fibrin(ogen) binding, and the platelet procoagulant 































































































































Figure 2. Deficiency of murine factor XI (FXI) and FXII impairs thrombus formation under coagulant conditions on plaque material ex vivo. 
Citrate-anticoagulated blood from F11−/−, F12−/−, F11−/−F12−/− and corresponding wild-type mice was recalcified with CaCl2/MgCl2 and per-
fused over murine plaque material at a shear rate of 1000 s−1 for 6 minutes. Human FXII (hFXII; 375 nmol/L [30 μg/mL]) was added before 
the experiment when indicated. A, Representative phase-contrast images and fluorescence images of fluorescein isothiocyanate (FITC)–
annexin A5–labeled procoagulant platelets (bars, 30 μm). B, Surface area coverage of deposited platelets. C, Frequency distribution of 
feature size of platelet–fibrin thrombi; estimated numbers of platelets per feature were 1 to 2, 2 to 8, 8 to 40, 40 to 130, and >130. D, Sur-
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activity (phosphatidylserine exposure) were strongly reduced 
(Figure 3A–3C). Notably, addition of purified human FXII 
fully restored the defective thrombus formation and plate-
let procoagulant activity. Control measurements performed 
with Phe-Pro-Arg chloromethylketone-anticoagulated blood 
showed that thrombus formation on plaque material was 
highly similar with blood from control and FXII-deficient 
subjects at these thrombin-inhibiting/noncoagulating condi-
tions (not shown).
To substantiate these findings, thrombus formation was 
assessed under coagulant conditions in control blood samples 
by pharmacological inhibition of FXIIa with CTI (50 μg/
mL) or recombinant infestin-4 human albumin fusion protein 
(250 μg/mL). Either inhibitor caused a 50% reduction in surface 
area coverage and procoagulant activity of platelets (Figure 4A 
and 4B). Dose–response experiments with recombinant infes-
tin-4 human albumin fusion protein (0.1–2.0 mg/mL) indi-
cated an optimal inhibitory effect at 250 μg/mL (not shown). 
Incubation of the blood with FVIIai (10 μg/mL) resulted in 
a significant reduction in thrombus formation and in a trend 
toward reduced platelet procoagulant activity (Figure 4).
Role of Human FXII in Plaque-Mediated Thrombin 
Generation and Clotting in Platelet-Rich Plasma
To confirm the effects of FXII inhibition and blockage of TF–
FVIIa interaction on platelet- and plaque-dependent coagu-
lation, clotting times were measured in recalcified human 
platelet-rich plasma (PRP). Addition of plaque homogenate 
reduced the time to Ca2+-triggered clot formation, which effect 
was partly antagonized with either CTI or FVIIai and fully 
antagonized by application of both inhibitors (Table I in the 
online-only Data Supplement). These data thus point to a key 
role of human FXII in fibrin clot formation in PRP, triggered 
by plaque material.
Knowing that thrombin provides a positive feedback loop 
by stimulation of platelet phosphatidylserine exposure and 
hence of platelet procoagulant activity,2 we examined in more 
detail the contribution of FXII to thrombin generation in PRP 
triggered by CaCl
2
 with(out) plaque material. The thrombin 
generation curve generated in control PRP in the presence 
of CaCl
2
 was absent in FXII-deficient PRP (Table II in the 
online-only Data Supplement). In control PRP, plaque mate-
rial caused a similar acceleration and increase in thrombin gen-
eration as collagen (Figure 5A). In contrast, in FXII-deficient 
PRP, plaque material and collagen triggered a slow-onset, low 
thrombin generation, whereas the addition of purified FXII 
normalized this process (Figure 5B). Thus, we concluded that 
FXII plays a key stimulating role in plaque-induced and plate-
let-dependent thrombin generation.
Localization of FXII in Human Thrombi 
Formed on Atherosclerotic Plaque Material
In whole-blood perfusion experiments over collagen ex vivo, 
the thrombogenic role of FXII has been explained by activated 















































































FXII def FXII def 
+hFXII





Figure 3. Deficiency of human factor XII 
(FXII) impairs thrombus formation under 
coagulant conditions on plaque mate-
rial ex vivo. Citrate-anticoagulated blood 
from an FXII-deficient subject (FXII <1%) 
or from 3 healthy control (Ctrl) subjects 
was recalcified with CaCl2/MgCl2 and 
perfused over human plaque material at 
500 s−1. Where indicated, patient blood 
samples were supplemented with human 
FXII (hFXII; 375 nmol/L). Shown are 
representative microscopic images and 
quantitative data of surface area cover-
age analysis of (A) platelet–fibrin thrombi, 
(B) AF647–annexin A5 labeling of phos-
phatidylserine-exposing platelets, and (C) 
OG488-fibrin(ogen) labeling. Bars, 30 μm. 


































































Figure 4. Pharmacological inhibition of factor XII (FXII) sup-
presses thrombus formation on human plaque material. Blood 
was perfused over human plaque material, as in Figure 3. Inhibi-
tors corn trypsin inhibitor (CTI; 50 μg/mL) or recombinant infes-
tin-4 human albumin fusion protein (rHA-infestin-4; 250 μg/mL) 
were present in the collecting tube during blood collection. Incu-
bation with active-site inactivated FVIIa (FVIIai; 10 μg/mL) was 
for 15 minutes before the experiment. Shown is deposition of all 
platelets (A) and phosphatidylserine-exposing platelets (B) at the 
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localization of FXII in thrombi formed on plaque material. 
Nonspecific binding sites on the thrombi were blocked by pre-
incubation with anti-goat serum, after which FXIIa was stained 
with a monoclonal mouse antibody, followed by an AF647-
labeled goat anti-mouse IgG. Stainings with an isotype control 
antibody followed by AF647 goat anti-mouse IgG or AF647 
goat anti-mouse IgG alone yielded no fluorescence. Labeling 
with the anti-FXIIa antibody showed a staining of fibrin fibers 
(Figure 6). This is compatible with a recent finding that FXIIa 
can interact with fibrin to modulate clot structure.21 Stacks of 
confocal fluorescence images indicated that, at the base of the 
thrombus near the plaque surface, the staining for FXIIa was 
punctuated at the outer edges of platelet thrombi and on fibrin 
fibers (Figure 6). With increasing z direction, toward the luminal 
part of the thrombus, the FXIIa staining became more intense 
and more evenly distributed. Interestingly, the FXIIa staining 
did not colocalize with AF568–annexin A5 staining indicative 
for phosphatidylserine-exposing platelets (Pearson, r=0.02), 
implying that these procoagulant platelets did not bind FXIIa.
Discussion
In the present article, we revealed a major role of the FXII-
driven intrinsic pathway of coagulation in arterial throm-
bus formation on atherosclerotic plaques. Evidence for the 
involvement of FXII came from an in vivo model of acute 
plaque rupture in atherosclerotic mouse arteries using 2 struc-
turally different pharmacological FXIIa inhibitors, from ex 
vivo flow experiments using blood of F12−/− mice and blood 
of a subject with severe deficiency in FXII (FXII level <1%). 
The FXII-dependent procoagulant effect of plaque material 
was also observed as an increase in thrombin generation in the 
presence of platelets. Interestingly, immunologic staining for 
FXIIa of thrombi containing platelets and fibrin pointed to an 
accumulation of FXIIa in the luminal-exposed regions of the 
thrombus. This likely is relevant, because these top regions 
are subjected to high shear gradients and hence most prone 
to embolization.22 The present findings significantly extend 
earlier data, using purified or plasma systems, demonstrating 
that FXIIa can interact with fibrin to modulate clot structure.21 
Taken together, this suggests that local, FXIIa-initiated throm-
bin and fibrin generation provides stabilization to the regions 
of a thrombus distant from the vascular TF. Recent studies 
in which anti-FXII and anti-FXIIa antibodies were found to 
reduce fibrin formation in an ex vivo perfusion system with 
human blood provide additional support for this idea.13,23
Although the binding sites of FXIIa on platelets have not 
been elucidated, our confocal microscopic studies indicate that 
FXIIa does not bind to phosphatidylserine-exposing platelets. 
This is of interest, because the majority of coagulation factors 
(FII, FV, FVII, FVIII, FIX, and FX) have been shown to bind 
to this population of activated platelets.2 In addition, we and 
others have shown that both collagen and polyphosphates are 
able to activate FXII,5,9 although it needs to be noted that the 
chain length of platelet-derived polyphosphates is relatively 
short for optimal FXII activation.24 Together with the present 
findings, this would advocate for a combined role of collagen, 
platelets, and fibrin in activation of the FXII pathway.
Our data indicate that the formation of platelet–fibrin 
thrombi on immobilized plaque material is similarly affected 
in blood from F12−/−, F11−/−, or F11−/−/F12−/− mice, thus sug-
gesting that the role of FXII in promoting atherothrombosis is 
B FXII deficient subject
Control subjectA




































Figure 5. Factor XII (FXII) pathway contributes to plaque-induced 
thrombin generation. Thrombin generation was measured in 
platelet-rich plasma (PRP; 1×108 platelets/mL), incubated with 
plaque material (0.28 mg wet tissue weight/mL) or collagen (5 
μg/mL), and triggered with CaCl2 (16.6 mmol/L). Preincubation 
of PRP was with human FXII (hFXII; 375 nmol/L), as indicated. 
Shown are representative thrombograms with PRP from a control 
subject (A) and an FXII-deficient subject (FXII <1%; B). Note the 
greatly delayed thrombin generation at FXII deficiency.
B 0 µm height C 30 µm D 50 µm
A Base
Top/luminal
Figure 6. Localization of factor XIIa (FXIIa) on luminal-exposed 
thrombus parts and on fibrin fibers. Citrate-anticoagulated blood 
was recalcified with CaCl2/MgCl2 and perfused over plaque 
material, as indicated for Figure 3. Thrombi on plaques were 
rinsed with HEPES buffer, blocked with anti-goat serum, and 
stained with mouse monoclonal antibody against FXIIa, followed 
by AF647-labeled goat anti-mouse IgG plus AF588–annexin A5, 
to detect procoagulant phosphatidylserine-exposing platelets. 
Shown are a gallery of high-resolution overlays of differential 
interference contrast and confocal images of representative 
thrombi formed on plaque material at increasing z direction 
(base→top/luminal; A) and enlargements at 0 (B), 30 (C), and 
50 (D) μm height. Note the increased red FXIIa staining in the 
z direction and the lack of colocalization of FXIIa with green-
labeled procoagulant platelets (bars, 20 μm). Data are represen-
tative for 3 independent experiments.D
ow
nloaded from
 http://ahajournals.org by on Septem
ber 15, 2021
Kuijpers et al  FXII in Thrombus Formation on Plaques  1679
mediated via activation of FXI. This is in line with several in 
vivo studies pointing to corresponding roles of FXII and FXI 
in thrombus formation in artificially damaged nonatheroscle-
rotic mouse vessels.3,5,10 Consistent with an FXI-dependent 
role of FXII in arterial thrombosis, an anti-FXI monoclonal 
antibody that specifically targets FXIIa-mediated FXI activa-
tion has been shown to suppress thrombus formation in mice 
and baboons.4,25
Studies by our group and others have elucidated a 
 coagulation-initiating role of atherosclerotic plaques via local-
ized activity of TF, whereas the contact activation pathway 
was not investigated here.6,7,26–28 In the present study, inhibi-
tor experiments using FVIIai similarly pointed to a role of TF 
in the initiation of thrombus formation after plaque rupture 
in vivo, whereas FXII may be more important at later stages 
of this process. It is tentative to relate this early effect of the 
TF–FVIIa pathway and later contribution of the FXII pathway 
with the fact that FVII deficiency in man is accompanied by 
severe bleeding, whereas deficiency in FXII is not.3,14 Notably, 
our findings contrast to a recently published article showing a 
lack of effect of CTI on plaque-induced platelet aggregation 
and thrombin generation in vitro.8 Differences in methodol-
ogy and procedures could explain this discrepancy. Of note, in 
our experiments, FXIIa inhibitors were always added directly 
during blood taking, and a CTI batch with high enzymatic 
activity (1.5 U/mL) was used. This procedure was followed to 
prevent residual ongoing FXIIa activity in the anticoagulated 
blood samples.
Whereas FXII in man or mouse is not required for normal 
hemostasis,3,14 we here demonstrate a promoting role for FXII 
in pathological thrombus formation after plaque rupture. This 
is in accordance with clinical evidence that elevated levels of 
FXII(a) positively associate with arterial thrombosis, isch-
emic stroke, and coronary heart disease.29–31 On the contrary, 
conflicting evidence exists on whether individuals with partly 
reduced FXII levels have an increased risk of cardiovascular 
disease (reviewed in Renné et al15 and Woodruff et al16). In 
this regard, the thrombus-destabilizing effect observed under 
conditions of reduced FXII activity needs more attention. 
Patients with a stroke or myocardial infarction mostly have 
thrombosis of the carotid or coronary artery and may present 
with symptomatic emboli that potentially give rise to (semi)
occlusive thrombi downstream in the vasculature. However, 
many patients also develop clinically asymptomatic emboliza-
tion,32 which remain for the major part without pathological 
consequences.33 The latter is in line with the emerging notion 
that limited instability may be considered as a natural phe-
nomenon in arterial thrombus formation.22
Also, in patients with FVII deficiency, thrombotic episodes, 
particularly deep venous thrombosis, have been reported 
with an incidence of 3% to 4%.34 Although the underlying 
mechanism is unclear, it seems that these are mostly related 
to surgery and the use of replacement therapy with FVIIa or 
prothrombin complex concentrate.34
In summary, the present results indicate that the coagula-
tion pathways triggered by TF–FVIIa and FXIIa have distinct 
but complementary roles in atherothrombus formation. The 
TF–FVIIa pathway contributes to initial thrombus buildup, 
whereas FXIIa bound to thrombi ensures stability of the 
thrombus in later phases.
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Atherothrombosis, characterized by atherosclerotic lesion disruption with superimposed thrombus formation, is the major cause of myocar-
dial infarction and ischemic stroke. In this article, we demonstrate that tissue factor– and factor XII (FXII)–triggered coagulation pathways 
play distinct but complementary roles in coagulation and atherothrombosis. Evidence for this comes from a recently in-house established in 
vivo model of acute plaque rupture using 2 structurally different pharmacological FXIIa inhibitors with good clinical potential and a compound 
which blocks tissue factor–FVIIa interactions, from ex vivo flow experiments using blood from F12−/− mice and from a subject with a defi-
ciency in FXII (<1%). Furthermore, with an FXIIa antibody, we demonstrate that FXIIa binds to thrombi and fibrin particularly at those areas 
which are most prone to embolization. We conclude that tissue factor–FVIIa interaction is needed for initial thrombus formation, whereas FXII 
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